SeaCrest Wealth Management LLC Invests $44,000 in Anavex Life Sciences Corp. (NASDAQ:AVXL)

SeaCrest Wealth Management LLC purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXLGet Rating) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,375 shares of the biotechnology company’s stock, valued at approximately $44,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lazard Asset Management LLC acquired a new position in shares of Anavex Life Sciences in the 2nd quarter worth approximately $26,000. Dana Investment Advisors Inc. acquired a new position in shares of Anavex Life Sciences during the 1st quarter valued at $132,000. Atria Wealth Solutions Inc. acquired a new position in shares of Anavex Life Sciences during the 1st quarter valued at $136,000. Liberty One Investment Management LLC lifted its position in shares of Anavex Life Sciences by 23.3% during the 1st quarter. Liberty One Investment Management LLC now owns 13,119 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 2,479 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Anavex Life Sciences during the 2nd quarter valued at $169,000. Institutional investors and hedge funds own 31.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Anavex Life Sciences in a research report on Wednesday, October 12th. They set a “sell” rating on the stock.

Anavex Life Sciences Trading Down 0.9 %

Shares of AVXL stock opened at $12.68 on Monday. The firm has a market capitalization of $988.32 million, a PE ratio of -21.49 and a beta of 0.79. The firm has a fifty day simple moving average of $11.17 and a two-hundred day simple moving average of $10.37. Anavex Life Sciences Corp. has a 12 month low of $7.13 and a 12 month high of $21.30.

Anavex Life Sciences Company Profile

(Get Rating)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome.

Read More

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXLGet Rating).

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.